%0 Journal Article
%T 我国上市公司独立董事制度的反思与完善路径<br>Reflection and Improvement Path of Independent Director System of Listed Companies in China
%A 吴轶雯
%J Open Journal of Legal Science
%P 6288-6293
%@ 2329-7379
%D 2023
%I Hans Publishing
%R 10.12677/OJLS.2023.116902
%X 我国上市公司独立董事制度的发展与完善一直是公司治理中亟待解决的热点问题，2023年9月4日最新施行的《上市公司独立董事管理办法》针对实践中存在的部分问题予以了完善，但就我国现阶段的立法而言仍存在较大的改进空间。为进一步完善上市公司独立董事制度，充分发挥独立董事的监督作用，体现独立董事于上市公司而言独立性、专业性的特点，本文从现有的法律架构设计出发，结合“康美药业案”这一典型案例，分析现有法律制度与司法实践的困境，并针对不足之处为独立董事制度的完善路径提出具体建议。具体而言，当前独立董事制度的设计未完全贴合立法背景，同时还存在与监事会的职能竞合、兼职独立董事的局限、激励机制的不足等方面的问题。因此，应当从外部体制机制以及上市公司和独立董事内部出发，改革独立董事的选聘机制，并探索建立专职独立董事制度，完善与建立独立董事激励机制。<br />
The development and improvement of the independent director system of listed companies in China has always been a hot issue to be solved in corporate governance, and the latest “Administrative Measures for Independent Directors of Listed Companies” which came into force on September 4, 2023 has been perfected to address some of the problems existing in practice, but there is still a large room for improvement in terms of the legislation of the current stage in China. In order to further improve the system of independent directors of listed companies, give full play to the su-pervisory role of independent directors, and reflect the independence and professionalism of independent directors in listed companies, this paper analyzes the dilemmas of the existing legal system and judicial practice from the existing legal framework design, combined with the typical case of “Kangmei Pharmaceuticals Case”, and focuses on the following this paper analyzes the dilemma of the existing legal system and judicial practice from the design of the existing legal structure, and puts forward specific suggestions for the improvement of the independent director system. Specifically, the design of the current independent director system is not fully adapted to the legislative background, and there are also problems of competing functions with the supervisory board, limitations of part-time independent directors, and insufficient incentive mechanisms. Therefore, the selection and recruitment mechanism of independent directors should be reformed from the perspective of the external institutional mechanism and the internal of listed companies and independent directors, and the establishment of a full-time independent director system should be ex-plored, as well as the improvement and establishment of an incentive mechanism for independent directors.
%K 独立董事，上市公司，康美药业案，董事义务<br>Independent Directors
%K Listed Companies
%K The Case of Kangmei Pharmaceuticals
%K Directors’ Obligations
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=76123